NCT04847453 2026-03-18
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
379 trialsNCT05092451 2026-03-18
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT06179888 2026-03-18
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06465316 2026-03-18
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06980480 2026-03-18
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda
Phase 3 Recruiting
NCT03412877 2026-03-17
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04634552 2026-03-17
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05201781 2026-03-17
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
NCT06615479 2026-03-17
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07477912 2026-03-17
MSTH-CAR001
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 1/2 Recruiting
NCT05438043 2026-03-16
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07095452 2026-03-16
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT04960579 2026-03-13
MM
Poseida Therapeutics, Inc.
Phase 1 Recruiting
NCT05652335 2026-03-13
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05827016 2026-03-13
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Recruiting
NCT05862012 2026-03-13
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Ichnos Sciences SA
Phase 1 Recruiting
NCT06138275 2026-03-13
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
Phase 2 Recruiting
NCT06158841 2026-03-13
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06604715 2026-03-13
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06768489 2026-03-13
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07081646 2026-03-13
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT07149857 2026-03-13
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07266441 2026-03-13
TRIlogy-3
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT01962636 2026-03-12
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Recruiting
NCT05552222 2026-03-12
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
NCT06832865 2026-03-12
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT07284758 2026-03-12
MOMENTUM
C4 Therapeutics, Inc.
Phase 2 Recruiting
NCT05519085 2026-03-11
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT06185751 2026-03-11
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Washington University School of Medicine
Phase 1 Recruiting
NCT06223516 2026-03-11
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT06623630 2026-03-11
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
Phase 1 Recruiting
NCT06976476 2026-03-11
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06192979 2026-03-09
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Phase NA Recruiting
NCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06083922 2026-03-06
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06375044 2026-03-06
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06569147 2026-03-06
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Phase 1/2 Recruiting
NCT07181941 2026-03-06
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT07454382 2026-03-06
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03633955 2026-03-05
REALIZE
University of Oklahoma
Phase 1 Recruiting
NCT05091372 2026-03-05
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05927571 2026-03-05
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT07073547 2026-03-05
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
AstraZeneca
Phase 1 Recruiting